HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

FDA Approves Adjuvant Pertuzumab Regimen for HER2+ Breast Cancer

December 21st 2017

The FDA has approved pertuzumab in combination with trastuzumab and chemotherapy as an adjuvant treatment for patients with HER2-positive early breast cancer at high risk for recurrence.

CHMP Issues Positive Opinion on Herzuma for HER2+ Breast, Gastric Cancers

December 19th 2017

The European Union’s CHMP has delivered a positive opinion for Herzuma (CT-P6), a trastuzumab (Herceptin) biosimilar in HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer.

Dr. Rimawi Discusses Patient Selection in HER2+ Breast Cancer

December 19th 2017

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses patient selection in the treatment of HER2-positive breast cancer.

Precision Medicine a Necessary Component in HER2+ Breast Cancer Care

December 18th 2017

Mothaffar Fahed Rimawi, MD, discusses the significance of precision medicine in HER2-positive breast cancer, as well as the possible role of immunotherapy for this specific population.

Dr. Tripathy Discusses Neratinib in HER2+ Breast Cancer

December 12th 2017

Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neratinib (Nerlynx) for the treatment of patients with HER2-positive breast cancer.

Trastuzumab Deruxtecan Impresses in HER2 Expressing Breast Cancers

December 9th 2017

Trastuzumab deruxtecan (ds-8201a), a HER2-targeting antibody-drug conjugate, demonstrated significant clinical activity in heavily pretreated patients with HER2-expressing metastatic breast cancers.

Dr. Brufsky on Implementing Pertuzumab in HER2+ Breast Cancer

December 8th 2017

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, on implementing pertuzumab (Perjeta) in the treatment of patients of HER2-positive breast cancer.

1-Year of Adjuvant Trastuzumab Remains Standard in HER2+ Breast Cancer

December 7th 2017

The phase III SOLD trial failed to demonstrate that DFS with 9 weeks of adjuvant trastuzumab was noninferior to the standard 12 months when the 2 regimens were combined with chemotherapy in women with early stage HER2-positive breast cancer.

Trastuzumab Disappoints in HER2-low Patient Cohort

December 6th 2017

A trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein has shown no significant efficacy, confounding investigators who launched the trial based on opposing results from 2 earlier studies.

Expert Emphasizes Importance of Neoadjuvant Therapy in HER2+ Breast Cancer

November 29th 2017

Patrick Borgen, MD, discusses the importance of neoadjuvant therapy in the treatment of patients with HER2-positive breast cancer.

Dr. Pusztai on Challenges With Neoadjuvant HER2 Therapy

November 28th 2017

Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discusses the challenges facing neoadjuvant treatment of patients with HER2-positive breast cancer

Adjuvant Treatment Evolving for HER2+ Breast Cancer

November 27th 2017

Sara M. Tolaney, MD, discusses the state of adjuvant treatment for patients with HER2-positive breast cancer.

Expert Highlights Expanding Options for HER2+ Breast Cancer

November 27th 2017

Lajos Pusztai, MD, discusses neoadjuvant and adjuvant treatment decisions for patients with HER2-positive breast cancer, as well as the potential of immunotherapy in the metastatic setting.

Dr. Borgen on Advancements With HER2+ Breast Cancer

November 17th 2017

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses advancements in the treatment landscape of HER2-positive breast cancer.

Dr. Brufsky Discusses Pertuzumab in HER2+ Breast Cancer

November 14th 2017

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.

Dr. Tolaney on the ATEMPT Trial for HER2+ Breast Cancer

November 9th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the ATEMPT trial for patients with HER2-positive breast cancer.

Neoadjuvant Treatment Evolving in HER2-Positive Breast Cancer

October 31st 2017

Elizabeth A. Mittendorf, MD, PhD, discusses the evolving neoadjuvant treatment landscape and other developments in the field of HER2-postive breast cancer.

Neratinib Offers Hope in Treatment of CNS Metastases in HER2+ Breast Cancer

October 25th 2017

Rachel A. Freedman, MD, discusses treating patients with HER2-positive breast cancer who develop CNS metastases, and the promise that neratinib holds in this patient population.

Hamilton Highlights Progress in HER2-Positive Breast Cancer

October 25th 2017

Erika P. Hamilton, MD, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Dr. Hamilton Discusses Tucatinib in HER2+ Breast Cancer

October 24th 2017

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses tucatinib in the treatment of patients with HER2-positive breast cancer.